24 HR Guanfacine 2 MG Extended Release Oral Tablet

1 INDICATIONS AND USAGE Guanfacine extended-release tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications [ see CLINICAL STUDIES ( 14 ) ]. Guanfacine extended-release tablets are central alpha 2A -adrenergic receptor agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications ( 1 , 14 ) .

Par Pharmaceutical Inc.

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] toxicity to various agents` `[3] nausea` `[4] off label use` `[5] completed suicide` `[6] drug abuse` `[7] fatigue` `[8] diarrhoea` `[9] drug interaction` `[10] vomiting`

5 years ago

OVAL WHITE A534 2 mg

5 years ago

A534 2 mg OVAL WHITE

16 HOW SUPPLIED/STORAGE AND HANDLING Guanfacine extended-release tablets are supplied in 1 mg, 2 mg, 3 mg, and 4 mg strength extended-release tablets in 100 count and 1000 count bottles. 1 mg 2 mg 3 mg 4 mg Color white white blue blue Shape round Caplet round Caplet Debossment (top/bottom) A533/ 1 mg A534/ 2 mg A536/ 3 mg A538/ 4 mg NDC number 100 count: 10370-533-01 100 count: 10370-534-01 100 count: 10370-536-01 100 count: 10370-538-01 1000 count: 10370-533-10 1000 count: 10370-534-10 1000 count: 10370-536-10 1000 count: 10370-538-10 Storage - Store at 20° to 25°C (68° to 77°F). [see USP Controlled Room Temperature].

More pills like OVAL A534 2 mg

Comments

8 years ago - Saturday, Aug 13, 2016, 4:11 pm

guanfacine er 2mg

Related Pills

24 HR Guanfacine 3 MG Extended Release Oral Tablet

Par Pharmaceutical Inc.

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site